Marker Therapeutics Inc (MRKR)

[erg61]

This was posted earlier in August/September by another member and I felt like reposting this as a reminder of the progress and potential that exists with TPIV:

Comparing milestones reveals no change, no delay, no deletion, no nothing...


Milestones defined on August 25th 2017

2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
3Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
4Q 2017: TPIV 100/110 File amended IND; initate phase 1b/2 HER2/neu + breast cancer study
4Q 2017/1Q 2018- TPIV100/110 Mayo Clinic to initate Phase 1b/2 HER2/nue + DCIS study
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.


Milestones defines on June 1st 2017

2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
4Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.




Report TOS